Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; poloxamer; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate type a; povidone; titanium dioxide; indigo carmine aluminium lake; hypromellose; purified talc; macrogol 4000 - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. chealembic is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,chealembic is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; sodium starch glycollate type a; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; indigo carmine aluminium lake; purified talc; macrogol 4000 - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. chealembic is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,chealembic is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; crospovidone; poloxamer; povidone; sodium starch glycollate type a; titanium dioxide; hypromellose; indigo carmine aluminium lake; purified talc; macrogol 4000 - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. chealembic is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,chealembic is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; sodium starch glycollate type a; microcrystalline cellulose; poloxamer; povidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. alembic deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,alembic deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: crospovidone; poloxamer; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; povidone; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. alembic deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,alembic deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; poloxamer; crospovidone; povidone; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. alembic deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,alembic deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; hypromellose; purified water; microcrystalline cellulose; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; hypromellose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; purified water; magnesium stearate; hyprolose; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.